DelMar Pharmaceuticals, Inc. Contracts & Agreements

Form of Stock Option Agreement under 2024 Equity Incentive Plan (Filed With SEC on November 15, 2024)

Waiver Agreement to Agreement and Plan of Merger, dated as of October 18, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc (Filed With SEC on October 21, 2024)

Form of Indemnification Agreement by and between TuHURA Biosciences, Inc and each of its directors and executive officers (Filed With SEC on October 21, 2024)

TuHURA Biosciences, Inc. 2024 Equity Incentive Plan (Filed With SEC on October 21, 2024)

Amendment to Executive Employment Agreement, dated October 4, 2024, by and between the Company and Robert E. Hoffman (Filed With SEC on October 7, 2024)

Waiver Agreement to Agreement and Plan of Merger, dated as of September 25, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc (Filed With SEC on September 25, 2024)

Form of Morphogenesis, Inc. Common Stock Purchase Warrant issued in Series A Preferred Offering (Filed With SEC on May 13, 2024)

Form of Morphogenesis, Inc. Common Stock Purchase Warrant, dated June 1, 2019, issued for advisory services (Filed With SEC on May 13, 2024)

Form of Morphogenesis, Inc. Common Stock Purchase Warrant issued in Series A-1 Preferred Stock Offering (Filed With SEC on May 13, 2024)

Form of Morphogenesis, Inc. Common Stock Purchase Warrant issued in Note Conversion Transaction (Filed With SEC on May 13, 2024)

Form of Morphogenesis, Inc. Common Stock Purchase Warrant issued in Series B Preferred Stock Offering (Filed With SEC on May 13, 2024)

Form of TuHURA Biosciences, Inc. Common Stock Warrant issued in TuHURA Note Financing (Filed With SEC on May 13, 2024)

Form of Convertible Promissory Note issued in TuHURA Note Financing (Filed With SEC on May 13, 2024)

Amended and Restated Equity Plan of Morphogenesis, Inc (Filed With SEC on May 13, 2024)

Form of Option Agreement under the Amended and Restated Equity Plan of Morphogenesis, Inc (Filed With SEC on May 13, 2024)

Second Amended and Restated Employment Agreement, dated March 29, 2024, between TuHURA Biosciences, Inc. and Dan Dearborn (Filed With SEC on May 13, 2024)

Second Amended and Restated Employment Agreement, dated March 29, 2024, between TuHURA Biosciences, Inc. and James Bianco, M.D (Filed With SEC on May 13, 2024)

Employment Agreement, dated December 19, 2023, between TuHURA Biosciences, Inc. and Dennis Yamashita (Filed With SEC on May 13, 2024)

Exclusive License Agreement, dated March 29, 2019, between Morphogenesis, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc., as amended (Filed With SEC on May 13, 2024)

Exclusive License Agreement, dated April 23, 2021, between Morphogenesis, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc., as amended (Filed With SEC on May 13, 2024)

Restated and Amended Exclusive License Agreement, effective September 7, 2022, between TuHURA Biopharma, Inc. and West Virginia Research Corporation (Filed With SEC on May 13, 2024)

Asset Purchase Agreement, dated January 26, 2023, between TuHURA Biopharma Inc. and Morphogenesis, Inc (Filed With SEC on May 13, 2024)

Agreement and Plan of Merger, dated as of April 2, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc (Filed With SEC on April 3, 2024)

Form of Kintara Support Agreement (Filed With SEC on April 3, 2024)

Form of TuHURA Support Agreement (Filed With SEC on April 3, 2024)

Form of Lock-Up Agreement (Filed With SEC on April 3, 2024)

Form of Contingent Value Rights Agreement (Filed With SEC on April 3, 2024)

Form of Placement Agency Agreement (Filed With SEC on October 24, 2023)

Form of Pre-Funded Warrant (Filed With SEC on October 24, 2023)

Form of Common Warrant (Filed With SEC on October 24, 2023)

Form of Placement Agent Warrant (Filed With SEC on October 24, 2023)

Form of Securities Purchase Agreement (Filed With SEC on October 24, 2023)

Sales Agreement (Filed With SEC on September 19, 2023)

Amendment to the 2017 Omnibus Equity Incentive Plan of Kintara Therapeutics, Inc (Filed With SEC on September 27, 2022)

Purchase Agreement, dated as of August 2, 2022, by and between Kintara Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 3, 2022)

Registration Rights Agreement, dated as of August 2, 2022, by and between Kintara Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 3, 2022)

Separation and General Release Agreement between the Company and Saiid Zarrabian, dated May 20, 2022 (Filed With SEC on May 24, 2022)

Form of Investor Warrant (Filed With SEC on April 13, 2022)

Form of Placement Agent Warrant (Filed With SEC on April 13, 2022)

Form of Securities Purchase Agreement, dated April 12, 2022, by and between Kintara Therapeutics, Inc. and the purchasers named therein (Filed With SEC on April 13, 2022)

Placement Agency Agreement, dated April 12, 2022, by and between Kintara Therapeutics, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on April 13, 2022)

Executive Employment Agreement, dated November 8, 2021, by and between the Company and Robert Hoffman (Filed With SEC on November 12, 2021)

Second Amended Employment Agreement, dated November 8, 2021, by and between the Company and Saiid Zarrabian (Filed With SEC on November 12, 2021)

Amendment to the 2017 Omnibus Equity Incentive Plan of Kintara Therapeutics, Inc (Filed With SEC on September 28, 2021)

Form of Investor Warrant (Filed With SEC on September 28, 2021)

Form of Pre-Funded Warrant (Filed With SEC on September 28, 2021)

Form of Wainwright Warrant (Filed With SEC on September 28, 2021)

Form of Securities Purchase Agreement, dated September 23, 2021 (Filed With SEC on September 28, 2021)

Engagement Agreement, dated September 10, 2021 (Filed With SEC on September 28, 2021)

First Amended Executive Employment Agreement, by and between Kintara Pharmaceuticals, Inc. and Saiid Zarrabian (Filed With SEC on November 12, 2020)

Description of Securities (Filed With SEC on September 18, 2020)

Amendment to the 2017 Omnibus Equity Incentive Plan of Kintara Therapeutics, Inc (Filed With SEC on September 18, 2020)

Form of Placement Agent Warrant (Filed With SEC on September 1, 2020)

Placement Agency Agreement, dated as of June 24, 2020, by and among DelMar Pharmaceuticals, Inc. and Aegis Capital Corp (Filed With SEC on August 21, 2020)

Form of Subscription Agreement (Filed With SEC on August 21, 2020)

Form of DelMar Support Agreement (Filed With SEC on June 16, 2020)

Form of Adgero Support Agreement (Filed With SEC on June 16, 2020)

Amended and Restated Employment Agreement, dated as of March 1, 2018, by and between Adgero Biopharmaceuticals Holdings, Inc. and John Liatos (Filed With SEC on June 16, 2020)

Employment Agreement, dated as of April 8, 2016, by and between Adgero Biopharmaceuticals Holdings, Inc. and Steven J. Rychnovsky (Filed With SEC on June 16, 2020)

Amendment No. 1 to Employment Agreement, Incentive Stock Option Grant Agreement and Nonqualified Stock Option Grant Agreement, dated as of February 8, 2017, by and between Adgero... (Filed With SEC on June 16, 2020)

Amendment No. 2 to Employment Agreement, dated as of April 6, 2018, by and between Adgero Biopharmaceuticals Holdings, Inc. and Steven J. Rychnovsky (Filed With SEC on June 16, 2020)

Amendment No. 3 to Employment Agreement, dated as of April 6, 2020, by and between Adgero Biopharmaceuticals Holdings, Inc. and Steven J. Rychnovsky (Filed With SEC on June 16, 2020)

Asset Purchase Agreement, dated as of November 26, 2012, by and between Adgero Biopharmaceuticals, Inc. and St. Cloud Investments, LLC (Filed With SEC on June 16, 2020)

Amendment to Asset Purchase Agreement, dated as of May 12, 2014, by and between Adgero Biopharmaceuticals, Inc. and St. Cloud Investments, LLC (Filed With SEC on June 16, 2020)

Agreement and Plan of Merger and Reorganization, dated as of June 9, 2020, by and among DelMar Pharmaceuticals, Inc., Adgero Acquisition Corp., and Adgero Biopharmaceuticals... (Filed With SEC on June 10, 2020)

Form of DelMar Support Agreement (Filed With SEC on June 10, 2020)

Form of Adgero Support Agreement (Filed With SEC on June 10, 2020)

Amendment to the 2017 Omnibus Equity Incentive Plan of DelMar Pharmaceuticals, Inc (Filed With SEC on September 9, 2019)

Form of Common Stock Purchase Warrant (Filed With SEC on August 15, 2019)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on August 15, 2019)

Form of Underwriter Warrant (Filed With SEC on August 15, 2019)

Warrant Agency Agreement, dated as of August 14, 2019, by and between DelMar Pharmaceuticals, Inc. and Mountain Share Transfer, LLC (Filed With SEC on August 15, 2019)

Form of Leak-Out Agreement, dated as of August 14, 2019 (Filed With SEC on August 15, 2019)

Underwriting Agreement, dated as of August 14, 2019, by and among DelMar Pharmaceuticals, Inc., Maxim Group LLC and Dawson James Securities, Inc (Filed With SEC on August 15, 2019)

Form of Underwriting Agreement (Filed With SEC on August 12, 2019)

Form of Warrant Certificate (Filed With SEC on August 12, 2019)

Form of Pre-Funded Warrant Certificate (Filed With SEC on August 12, 2019)

Form of Underwriters Warrant (Filed With SEC on August 12, 2019)

Form of Warrant Agency Agreement (Filed With SEC on August 12, 2019)

Form of Investor Warrant (Filed With SEC on June 3, 2019)

Form of Placement Agent Warrant (Filed With SEC on June 3, 2019)

Placement Agency Agreement, dated June 3, 2019 among DelMar Pharmaceuticals, Inc., Maxim Group LLC and Dawson James Securities, Inc (Filed With SEC on June 3, 2019)

Form of Purchase Agreement, dated as of June 3, 2019 among DelMar Pharmaceuticals, Inc. and the purchasers thereunder (Filed With SEC on June 3, 2019)

Form of Dealer Manager Agreement (Filed With SEC on May 23, 2019)

Form of Warrant Agreement (Filed With SEC on May 23, 2019)

Form of Warrant Certificate (Filed With SEC on May 23, 2019)

Form of Non-Transferable Subscription Rights Certificate (Filed With SEC on May 23, 2019)

Form of Dealer-Manager Warrant Certificate (Filed With SEC on May 23, 2019)

Form of Warrant Exercise and Exchange Agreement, dated as of November 25, 2018, by and between DelMar Pharmaceuticals, Inc. and the Exercising Holders (Filed With SEC on November 26, 2018)

Form of Leak-Out Agreement, dated as of November 25, 2018, by and between DelMar Pharmaceuticals, Inc. and the Exercising Holders (Filed With SEC on November 26, 2018)

Form of Indemnification Agreement (Filed With SEC on June 25, 2018)

Employment Agreement, dated May 21, 2018, by and between DelMar Pharmaceuticals, Inc. and Mr. Zarrabian (Filed With SEC on May 22, 2018)

Del Mar Pharmaceuticals (BC) Ltd. 2013 Amended and Restated Stock Option Plan (Filed With SEC on May 15, 2018)

Form of Del Mar Pharmaceuticals (BC) Ltd. 2013 Amended and Restated Stock Option Plan Option Grant Agreement (Filed With SEC on May 15, 2018)

Form of DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan Option Grant Agreement (Filed With SEC on May 15, 2018)

Settlement Agreement, dated January 1, 2018, between Delmar Pharmaceuticals, Inc. and Jeffrey Bacha (Filed With SEC on February 14, 2018)

DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan (As Amended and Restated Effective as of February 1, 2018) (Filed With SEC on February 14, 2018)

Agreement, effective as of November 3, 2017 between the Company and Mr. Zarrabian (Filed With SEC on November 8, 2017)

Form of Indemnification Agreement (Filed With SEC on November 8, 2017)

Form of Warrant (Filed With SEC on September 21, 2017)

Form of Purchase Agreement, dated as of September 20, 2017 among DelMar Pharmaceuticals, Inc. and the purchasers thereunder (Filed With SEC on September 21, 2017)

Engagement Letter, dated September 17, 2017 between DelMar Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on September 21, 2017)

COMMONSTOCK PURCHASE WARRANT DELMARPHARMACEUTICALS, INC. (Filed With SEC on April 13, 2017)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on April 13, 2017)

430 Park Avenue| New York, New York 10022 | 212 ###-###-#### | www.hcwco.com Member: FINRA/SIPC (Filed With SEC on April 13, 2017)

EXECUTIVEEMPLOYMENT AGREEMENT (Filed With SEC on February 10, 2017)

AMENDMENTTO CONSULTING AGREEMENT (Filed With SEC on February 10, 2017)

DELMARPHARMACEUTICALS, INC. SECURITIESPURCHASE AGREEMENT (Filed With SEC on May 5, 2016)

DELMAR PHARMACEUTICALS, INC. ROYALTYAGREEMENT (Filed With SEC on May 5, 2016)

DELMARPHARMACEUTICALS, INC. COMMON STOCK WARRANT (Filed With SEC on May 5, 2016)

AMENDMENTNO. 1 TO PLACEMENT AGENT WARRANT (Filed With SEC on December 31, 2015)

DELMAR PHARMACEUTICALS, INC. AUDIT COMMITTEE CHARTER A. Purpose and Scope (Filed With SEC on September 3, 2015)

ADVISORY AGREEMENT (Filed With SEC on July 15, 2015)

FORM OF WARRANT COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC. (Filed With SEC on July 9, 2015)

U.S.SUBSCRIPTION AGREEMENT (Filed With SEC on July 9, 2015)

CANADIAN SUBSCRIPTION AGREEMENT (Filed With SEC on July 9, 2015)

AMENDMENTNO. 1 TO ESCROW AGREEMENT (Filed With SEC on June 30, 2015)

COMMONSTOCK PURCHASE WARRANT DELMARPHARMACEUTICALS, INC. (Filed With SEC on June 23, 2015)

U.S. SUBSCRIPTION AGREEMENT (Filed With SEC on June 23, 2015)

CANADIAN SUBSCRIPTION AGREEMENT (Filed With SEC on June 23, 2015)

ESCROWAGREEMENT (PUBLIC OFFERING) (Filed With SEC on June 23, 2015)

DELMAR PHARMACEUTICALS, INC. [____] Shares of Common Stock And [____]Warrants to Purchase One Shareof Common Stock PLACEMENT AGENT AGREEMENT (Filed With SEC on June 12, 2015)

DELMAR PHARMACEUTICALS, INC. [____] Shares of Common Stock and [____] Class A Warrants to Purchase One Share of Common Stock and [____] Class B Warrantsto Purchase One Share of... (Filed With SEC on May 12, 2015)

WARRANT AGENTAGREEMENT (Filed With SEC on May 12, 2015)

[CLASS A/CLASS B] COMMON STOCK PURCHASEWARRANT DELMAR PHARMACEUTICALS, INC. (Filed With SEC on May 7, 2015)

CONSULTING AGREEMENT (Filed With SEC on April 10, 2015)

EXCHANGEAGREEMENT (Filed With SEC on January 7, 2015)

Form of Investor Warrant Amendment (Filed With SEC on November 6, 2014)

Form of Dividend Warrant Amendment (Filed With SEC on November 6, 2014)

Exchange Agreement, dated September 30, 2014 (Filed With SEC on October 3, 2014)

Patent Assignment Agreement, dated September 12, 2010, between DelMar (BC) and Valent (Filed With SEC on March 14, 2013)

Amendment, dated January 21, 2013, to Patent Assignment Agreement, dated September 12, 2010, between DelMar (BC) and Valent (Filed With SEC on March 14, 2013)

Loan Agreement, dated February 3, 2011, between DelMar (BC) and Valent (Filed With SEC on March 14, 2013)

Consulting Agreement, dated August 1, 2011, between DelMar (BC) and Jeffrey Bacha (Filed With SEC on March 14, 2013)

Consulting Agreement, dated August 1, 2011, between DelMar (BC) and Dennis Brown (Filed With SEC on March 14, 2013)

Consulting Agreement, dated August 1, 2011, between DelMar (BC) and William Garner (Filed With SEC on March 14, 2013)

Consulting Agreement, dated February 1, 2013, between DelMar (BC) and Scott Praill (Filed With SEC on March 14, 2013)

Category

Industry

Companies

Contracts

DelMar Pharmaceuticals, Inc. Contracts & Agreements